Drug survival and predictor factors for discontinuation of methotrexate in psoriasis: a real-life multicenter study.

Drug survival is useful to evaluate long-term drug performance in daily practice. The aim of this study was to evaluate drug survival for methotrexate (MTX) monotherapy in patients with plaque-type psoriasis.We reviewed 3,512 follow-up charts of patients with psoriasis at five tertiary referral centers between January 2012 and January 2020. We analyzed baseline data and treatment outcomes of patients under MTX monotherapy. Drug survival was analyzed using Kaplan-Meier and Cox regression analyses.Patients with psoriasis who were treated with MTX monotherapy were enrolled (N = 649). The median duration of drug survival was 15 months (95% CI: 13.2-16.8). The overall drug survival rate was 54.7%, 17.4%, and 8% after 1, 3, and 5 years, respectively. The main reasons for discontinuation were adverse effects (n = 209, 32.2%) and inefficacy (n = 105, 15.6%). Based on multivariate Cox regression analysis, the presence of nausea/vomiting (HR: 2.01, 95% CI: 1.49-2.71; P 

View the full article @ International journal of dermatology

Get PDF with LibKey
Authors: Tugba Ozkok Akbulut, Filiz Topaloglu Demir, Ilteris Oguz Topal, Asude Kara Polat, Ayse Serap Karadag, Melek Aslan Kayiran, Ezgi Ozkur, Ilknur Kıvanc Altunay